U.S. markets close in 5 hours 54 minutes
  • S&P 500

    4,372.64
    -60.35 (-1.36%)
     
  • Dow 30

    34,154.21
    -430.67 (-1.25%)
     
  • Nasdaq

    14,786.20
    -257.76 (-1.71%)
     
  • Russell 2000

    2,195.05
    -41.82 (-1.87%)
     
  • Crude Oil

    71.14
    -0.83 (-1.15%)
     
  • Gold

    1,759.20
    +7.80 (+0.45%)
     
  • Silver

    22.36
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1721
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    1.3350
    -0.0350 (-2.55%)
     
  • GBP/USD

    1.3670
    -0.0068 (-0.49%)
     
  • USD/JPY

    109.6000
    -0.2950 (-0.27%)
     
  • BTC-USD

    44,028.77
    -3,357.35 (-7.09%)
     
  • CMC Crypto 200

    1,099.82
    -34.57 (-3.05%)
     
  • FTSE 100

    6,895.66
    -67.98 (-0.98%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Selecta's (SELB) Q3 Loss Narrower-Than Expected, Revenues Beat

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Selecta Biosciences Inc. SELB is engaged in developing tolerogenic therapies that selectively mitigate unwanted immune responses. The company’s lead pipeline candidate SEL-212 is a combination of its ImmTOR immune tolerance platform and a therapeutic uricase enzyme pegadricase.

Selecta along with Swedish Orphan Biovitrum AB (Sobi) is evaluating SEL-212 in the phase III DISSOLVE program for addressing chronic refractory gout. Another head-to-head phase II COMPARE study is investigating SEL-212 versus pegloticase to treat patients with chronic refractory gout.

Selecta has out-licensed SEL-212 to Sobi as the latter is now responsible for the development and commercial activities in all territories outside China.

Selecta’s surprise record has been mixed so far as its bottom line beat estimates in two of the trailing four quarters and lagged the same on the other two occasions, the average miss being 42.79%. In the last reported quarter, Selecta witnessed a negative earnings surprise of 153.13%.

Currently, Selecta has a Zacks Rank #5 (Strong Sell). We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Selecta reported a loss of 0.09 cents per share in the third quarter of 2020, which was narrower than the Zacks Consensus Estimate of a loss of 12 cents.

Revenues: Selecta generated total revenues of $4.6 million during the third quarter beating the Zacks Consensus Estimate of $3.75 million.

Key Stats: Selecta generated $4.3 million revenue under the license agreement with Sobi and $0.3 million for under the collaboration agreement with Sarepta.

2020 Guidance: Selecta expects that its cash, cash equivalents and marketable securities as of September 30, 2020 will be able to fund its anticipated operating expenses and capital expenditure requirements at least through the first quarter of 2023.

Share Price Impact: Shares were down 7.9% in pre-market trading.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Selecta Biosciences, Inc. (SELB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research